Share price · MRK
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
See what was announced around each unusual move
Research flags the days this stock moved far more than its sector fund, lists the news, filings and earnings dated around each one, and shows how much of its unusual movement fell on each asset's announcements.
Assets
(34 total)
| Target & Modality | |||
|---|---|---|---|
Doravirine(Pifeltro) | Approved | HIV reverse transcriptaseSmall molecule | HIV |
ensifentrine(Ohtuvayre) | Approved | PDE3/PDE4Small molecule | Chronic Obstructive Pulmonary Disease |
Ertugliflozin(Steglatro) | Approved | SGLT2Small molecule | Type 2 Diabetes |
Finerenone(Kerendia) | Approved | Mineralocorticoid receptorSmall molecule | Heart FailureChronic Kidney Disease |
| Approved | Type I interferon receptor | Chronic Hepatitis B | |
mometasone furoate/formoterol fumarate(Dulera / Zenhale) | Approved | Glucocorticoid receptor; Beta-2 adrenergic receptorSmall molecule | Asthma |
| Approved | PARPSmall molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Approved | PD-1Monoclonal antibody | Non-Small Cell Lung CancerBreast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Approved | PD-1Monoclonal antibody | Non-Small Cell Lung Cancer | |
Raltegravir(Isentress) | Approved | HIV integraseSmall molecule | HIV |
Sitagliptin(Januvia) | Approved | DPP-4Small molecule | Type 2 Diabetes |
Vericiguat(Verquvo) | Approved | Soluble guanylate cyclaseSmall molecule | Heart Failure |
| Phase 3 | HIV reverse transcriptaseSmall molecule | HIV | |
| Phase 3 | KRAS G12CSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 3 | PCSK9Peptide | Atherosclerotic Cardiovascular Disease |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Unlock insider transactions
Research includes SEC Form 4 insider transactions: filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Unlock institutional holders
Research includes quarterly SEC 13F institutional ownership: top holders, aggregate positions and quarter-over-quarter context.